Literature DB >> 33390817

Vasculotide restores the blood-brain barrier after focused ultrasound-induced permeability in a mouse model of Alzheimer's disease.

Madelaine Lynch1,2, Stefan Heinen1, Kelly Markham-Coultes1, Meaghan O'Reilly3,4, Paul Van Slyke5, Daniel J Dumont1,4, Kullervo Hynynen3,4, Isabelle Aubert1,2.   

Abstract

Focused ultrasound (FUS) is used to locally and transiently induce blood-brain barrier (BBB) permeability, allowing targeted drug delivery to the brain. The purpose of the current study is to evaluate the potential of Vasculotide to accelerate the recovery of the BBB following FUS disruption in the TgCRND8 mouse model of amyloidosis, characteristic of Alzheimer's disease (AD). Accelerating the restoration of the BBB post-FUS would represent an additional safety procedure, which could be beneficial for clinical applications.
Methods: TgCRND8 mice and their non-transgenic littermates were treated with Vasculotide (250 ng, intraperitoneal) every 48 hours for 3 months. BBB permeability was induced using FUS, in presence of intravenously injected microbubbles, in TgCRND8 and non-transgenic mice, and confirmed at time 0 by MRI enhancement using the contrast agent gadolinium. BBB closure was assessed at 6, 12 and 20 hours by MRI. In a separate cohort of animals, BBB closure was assessed at 24-hours post-FUS using Evans blue injected intravenously and followed by histological evaluation.
Results: Chronic Vasculotide administration significantly reduces the ultra-harmonic threshold required for FUS-induced BBB permeability in the TgCRND8 mice. In addition, Vasculotide treatment led to a faster restoration of the BBB following FUS in TgCRND8 mice. BBB closure after FUS is not significantly different between TgCRND8 and non-transgenic mice. BBB permeability was assessed by gadolinium up to 20-hours post-FUS, demonstrating 87% closure in Vasculotide treated TgCRND8 mice, as opposed to 52% in PBS treated TgCRND8 mice, 58% in PBS treated non-transgenic mice, and 74% in Vasculotide treated non-transgenic mice. In both TgCRND8 mice and non-transgenic littermates the BBB was impermeable to Evans blue dye at 24-hours post-FUS.
Conclusion: Vasculotide reduces the pressure required for microbubble ultra-harmonic onset for FUS-induced BBB permeability and it accelerates BBB restoration in a mouse model of amyloidosis, suggesting its potential clinical utility to promote vascular health, plasticity and repair in AD. © The author(s).

Entities:  

Keywords:  Alzheimer's disease; Vasculotide; blood-brain barrier; transcranial focused ultrasound

Year:  2021        PMID: 33390817      PMCID: PMC7757142          DOI: 10.7150/ijms.36775

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


  6 in total

Review 1.  The Applications of Focused Ultrasound (FUS) in Alzheimer's Disease Treatment: A Systematic Review on Both Animal and Human Studies.

Authors:  Xiaodan Liu; S Sta Maria Naomi; Wu Lin Sharon; E Jacobs Russell
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

2.  Treatment With an Angiopoietin-1 Mimetic Peptide Improves Cognitive Outcome in Rats With Vascular Dementia.

Authors:  Lauren Culmone; Brianna Powell; Julie Landschoot-Ward; Alex Zacharek; Huanjia Gao; Elizabeth L Findeis; Ayesha Malik; Mei Lu; Michael Chopp; Poornima Venkat
Journal:  Front Cell Neurosci       Date:  2022-05-06       Impact factor: 6.147

Review 3.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

Review 4.  Making waves: how ultrasound-targeted drug delivery is changing pharmaceutical approaches.

Authors:  Lauren J Delaney; Selin Isguven; John R Eisenbrey; Noreen J Hickok; Flemming Forsberg
Journal:  Mater Adv       Date:  2022-02-23

Review 5.  Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers.

Authors:  Mirna Lechpammer; Rohan Rao; Sanjit Shah; Mona Mirheydari; Debanjan Bhattacharya; Abigail Koehler; Donatien Kamdem Toukam; Kevin J Haworth; Daniel Pomeranz Krummel; Soma Sengupta
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

Review 6.  Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?

Authors:  Hugo Alarcan; Yara Al Ojaimi; Debora Lanznaster; Jean-Michel Escoffre; Philippe Corcia; Patrick Vourc'h; Christian R Andres; Charlotte Veyrat-Durebex; Hélène Blasco
Journal:  J Pers Med       Date:  2022-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.